TESARO

Waltham, United States Founded: 2010 • Age: 16 yrs Listed Acquired By GSK
Oncology therapeutics for cancer treatment and nausea prevention are developed.

About TESARO

TESARO is a Healthcare company based in Waltham (United States) founded in 2010, and was acquired by GSK in December 2018. Oncology therapeutics for cancer treatment and nausea prevention are developed. It operates on a Direct-to-Consumer (D2C) model. TESARO has raised $161 million across 6 funding rounds from investors including Oracle, Kleiner Perkins and T. Rowe Price. TESARO offers products and services including PARP Inhibitors. Its focus areas include Pharmaceuticals and Oncology. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.

Company details

TESARO, based in the United States, is engaged in the development of oncology-focused pharmaceutical products. The company specializes in PARP inhibitors, which are used in the treatment of ovarian cancer, particularly for patients with genetic mutations such as BRCA. These inhibitors are recognized for their potential to transform cancer treatment by preventing cancer cells from repairing damaged DNA. TESAROs solutions are applied in second-line maintenance therapy and show promise for broader application in first-line maintenance settings across multiple cancer types.

Operational Areas
Key Metrics
  • Total Equity Funding
    $161M (USD)

    in 6 rounds

  • Investors
    Oracle

    & 10 more

  • Acquired by
    GSK

    (Dec 2018)

Products & Services of TESARO

TESARO offers a comprehensive portfolio of products and services, including PARP Inhibitors.

PARP Inhibitors
Oncology Drugs

Medicines for treating ovarian cancer are developed here.

Apps and channels of TESARO

its YouTube channel ViiV Healthcare has 133 subscribers and 30 videos.

ViiV Healthcare
YouTube 133 subscribers 30 videos Autos & Vehicles
Open channel

Videos from TESARO

The most watched videos on TESARO's YouTube channel, ViiV Healthcare (133 subscribers). Click a video to play it here.

Bridging the gap between clinical trials and real life in HIV care
532.5K views
The potential of bNAbs
11.4K views
Take My Hand
2.2K views
We can end the HIV epidemic, FULL STOP.
1.9K views

More on ViiV Healthcare.

Funding Insights of TESARO

TESARO has successfully raised a total of $161M across 6 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $161M
  • Total Rounds 6
  • First Round $60M

    (May 2010)

  • Investors Count 10

All 6 funding rounds of TESARO with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jun 2018Post-IPO––
Nov 2017$500MDebt – Conventional––
–
Apr 2016$50MPost-IPO––
–
Feb 2016$155MPost-IPO––
Jun 2011$101MSeries B–Kleiner Perkins
May 2010$60MSeries A–New Enterprise Associates
–
Valuation history

11 investors in total: 11 institutional.

Investors in TESARO

TESARO has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include Oracle, Kleiner Perkins and T. Rowe Price.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Global private equity investments are managed by the firm.
athyrium.comNew York, United States
Early-stage investing in IT and healthcare ventures.
interwest.com
Venture capital investments are offered to startups by NEA.
nea.comMenlo Park, United States
Venture capital firm investing in early-stage tech startups
1972kleinerperkins.comMenlo Park, United States
Private equity and hedge fund investments in healthcare are managed.
ally-bridge.comHong Kong, China
VC firm focusing on life science sector
pappas-capital.comDurham, United States
Healthcare ecosystem is supported through investment and innovation by Deerfield.
deerfield.comNew York, United States
Sovereign Wealth Fund of Government of Australia
futurefund.gov.auMelbourne, Australia
Diversified asset management services are provided to investors globally.
1937troweprice.comBaltimore, United States
Hybrid cloud infrastructure solutions are delivered for business management.
1977oracle.comAustin, United States
Premium access

Investor details for TESARO

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of TESARO

19 people are tracked at TESARO (8 in leadership, 11 in team).

NameRoleGroup
Mary Lynne Hedley
President, Chief Operating OfficerLeadership
Jennifer Jackson
Senior Vice President, Global Regulatory Affairs & Quality AssuranceLeadership
William Aitchison
Senior Vice President, Technical OperationsLeadership
Allene Diaz
Senior Vice President, Global Commercial Development and Program StrategyLeadership
Erin Wilkie
Director, Global Brand AnalyticsLeadership
Pattie Skeens
Associate Director, Gcp/glp Quality AssuranceLeadership
Dennis L. Vargo
Vice President And Head Of PharmacovigilanceLeadership
Joachim Borchardt-Wagner
Market Access Director DACHLeadership
Blanca Gago Cao
Executive Office AssistantTeam
Michele Musial
Executive AssistantTeam
Kristina Sukennik Pharmd
Drug Safety/pv Specialist Via Gemini Staffing ConsultantsTeam
Zachary Yates
Senior ManagerTeam
Eileen Troy
Manager Quality ControlTeam
Jeffrey Flebbe
Manager, Quality ControlTeam
Nianyun Chen (Chenny)
Senior ManagerTeam
Dominique Demaria
Proxy AuditorTeam
Joydeep Basu
QA ManagerTeam
Zina D.
Manager, Commercial Quality ControlTeam
Susan Madden
Executive Administrative AssistantTeam
Premium access

Complete people profiles for TESARO

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of TESARO

5 dated milestones of TESARO across 8 years, from founding to its latest funding, stage changes and deals.

  1. Founded TESARO is founded.
  2. Funding First funding round of $60.0M.
  3. IPO Lists on the stock exchange (IPO).
  4. Funding Latest funding round, Post-IPO,.
  5. Exit Acquired by GSK.

Competitors of TESARO

TESARO has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
modernatx.com2010Cambridge, United States$2.78B1,312
mRNA-based therapeutics for diseases including cancer and infections are developed.
beigene.com2010Cambridge, United States$172M1,090
Targeted and immune-oncology drugs for cancer treatment are developed.
incyte.com1991Wilmington, United States1,387
Small molecules are developed for cancer and skin disease treatments.
Premium access

Detailed competitors of TESARO

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of TESARO

Websites that share an audience with TESARO (tesarobio.com).

Similar websites

Websites whose visitors overlap most with TESARO. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
centerwatch.com
100%
158.2K#254,725View details
progenics.com
94%
View details
cancer.gov
92%
3.1M#23,691View details
fiercebiotech.com
89%
858.3K#81,022View details
dana-farber.org
80%
549.8K#114,885View details
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
Premium access

All 11 similar websites and full traffic analytics for TESARO

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 11 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Oncology

3 companies that operate in the same segment as TESARO (Oncology) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Digital sequencing technology for cancer detection is developed.
2012Redwood City, California, United StatesUSD 557.5 MUSD 982.02 M4,867
Circulating tumor DNA is screened for early cancer detection.
2016Menlo Park, California, United StatesUSD 2 BUSD 147.17 M1,141
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Tesaro

Premium access

Complete news archive for TESARO

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about TESARO

TESARO was founded in 2010.

TESARO is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.

TESARO is a funded company, having raised a total of $161M across 6 funding rounds to date. The company's 1st funding round was a Series A of $60M, raised on May 2010.

TESARO, based in the United States, is engaged in the development of oncology-focused pharmaceutical products. The company specializes in PARP inhibitors, which are used in the treatment of ovarian cancer, particularly for patients with genetic mutations such as BRCA. These inhibitors are recognized for their potential to transform cancer treatment by preventing cancer cells from repairing damaged DNA. TESAROs solutions are applied in second-line maintenance therapy and show promise for broader application in first-line maintenance settings across multiple cancer types.

TESARO's top competitors include Moderna, BeiGene and Incyte.

TESARO offers PARP Inhibitors.

TESARO has 11 investors. Key investors include Oracle, Kleiner Perkins, T. Rowe Price, GSK, and Athyrium Capital Management.

Yes. TESARO was acquired by GSK in December 2018.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available